Name: Hepatic Encephalopathy: Pathophysiology and Treatment (en Inglés)
Price: 5077.24 MXN
Availability: InStock
Author: Butterworth, Roger F. ; Layrargues, Gilles Pomier
ISBN: 9781461288510

Envío gratis

portada Hepatic Encephalopathy: Pathophysiology and Treatment (en Inglés)

Formato

Libro Físico

Autor

Roger F. Butterworth

Gilles Pomier Layrargues

Editorial

Humana

Idioma

Inglés

N° páginas

622

Encuadernación

Tapa Blanda

Dimensiones

23.4 x 15.6 x 3.3 cm

Peso

0.89 kg.

ISBN13

9781461288510

Categorías

Gastroenterología
Neurología y neurofisiología clínicas
Neurociencias
Jardinería

Hepatic Encephalopathy: Pathophysiology and Treatment (en Inglés)

Roger F. Butterworth (Autor) · Gilles Pomier Layrargues (Autor) · Humana · Tapa Blanda

Libro Nuevo

$ 5,077.24

$ 9,231.35

Ahorras: $ 4,154.11

45% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Viernes 02 de Agosto y el Jueves 15 de Agosto.

Lo recibirás en cualquier lugar de México entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Hepatic Encephalopathy: Pathophysiology and Treatment (en Inglés)"

Hepatic Encephalopathy (HE) is a neuropsychiatric disorder resul t- ing from liver failure. HE may be associated with fulminant (acute) hepatic failure or chronic liver disease with portal-systemic shunting. The latter condition is characterized neuropathologically by astro- cytic rather than neuronal changes (Alzheimer Type II astrocytosis). The former is frequently accompanied by cerebral edema. Several hypotheses have been proposed to explain the pathogene- sis of HE. These include: 1. A toxic action of a substance (or substances) such as ammonia on brain function 2. A deficit of cerebral energy metabolism 3. Neurotransmitter changes, and, more recently 4. The role of "endogenous benzodiazepines. " This volume summarizes the results of a symposium held in Val David, Quebec from October 3D-November I, 1988, that was devoted to an evaluation of the evidence for and against the various hypothe- ses of HE. Data from studies in patients, in experimental (animal) models of HE, and in cultured cell preparations were discussed. In addition, a review of available approaches to the treatment and man- agement of HE was included. The therapeutic use of lactulose, anti- biotics, dietary treatment, and branched-chain amino acid treatments were included, as well as the results of preliminary studies of the therapeutic use of the benzodiazepine antagonist, flumazenil. Roger F. Butterworth, PhD Gilles Pomier Layrargues, MD v Acknowledgments The symposium was made possible by the generous financial assistance of: Hoffman-La Roche Ltd.